[ad_1]
Johnson & Johnson JNJ was one of many worst-performing Dow Jones Industrial Common shares within the first half of 2024. Traders and analysts can be on the lookout for the corporate to indicate progress from a blended first quarter when second-quarter monetary outcomes are reported Wednesday, July 17.
Earnings Estimates: Analysts count on Johnson & Johnson to report second-quarter income of $22.31 billion, in response to knowledge from Benzinga Professional.
The corporate reported income of $25.53 billion in final 12 months’s second quarter, which means analysts see a income decline on a year-over-year foundation. Johnson & Johnson has crushed income estimates in six of the previous 10 quarters and 4 of the final 5 quarters.
Analysts count on Johnson & Johnson to report second-quarter earnings per share of $2.70, which might be a decline from $2.80 reported in final 12 months’s second quarter. The corporate has crushed analysts’ estimates for earnings per share within the final 10 straight quarters.
Steering from the corporate requires full 12 months gross sales of $88.7 billion to $89.1 billion, which was forward of earlier consensus estimates. The corporate estimates that full fiscal 12 months earnings per share can be in a variety of $10.57 to $10.72.
What Analysts Are Saying: Johnson & Johnson is making noise within the intraocular lens section, Stifel analyst Thomas Stephan stated in a brand new investor notice.
The analyst surveyed 93 U.S. ophthalmologists to seek out out which IOLs had been being favored over others.
“JNJ’s Odyssey is already exhibiting spectacular early survey outcomes,” Stphen stated.
The unhealthy information for Johnson & Johnson could possibly be that Odyssey might “cannibalize different JNJ lenses” like Synergy, the analyst stated.
The analyst has a Purchase ranking on Alcon ALC and RxSight RXST within the sector and sees the potential of Johnson & Johnson shedding extra market share.
“RXST’s LAL expectedly is poised to realize general IOL share in 2025; ALC share loss seems average, and doubtlessly lower than JNJ.”
Steering from analysts and the corporate are affordable for Johnson & Johnson, Goldman Sachs not too long ago stated.
The agency reiterated a Impartial ranking on Johnson & Johnson and has a $160 value goal.
Goldman Sachs estimated Johnson & Johnson may have second-quarter income of $22.5 billion and earnings per share of $2.72.
The analyst cautioned that development might sluggish for the corporate citing the biosimilar entry of Stelara, the corporate’s largest product.
Learn Additionally: 5 Largest Winners, 5 Largest Losers From Dow Jones Industrial Common In First Half 2024
Key Objects to Watch: Psoriasis drug Stelara had gross sales of $2.45 billion within the first quarter, which was under estimates. Analysts and buyers will seemingly be on the lookout for this quantity to enhance forward of competitors in 2025.
A number of most cancers medication noticed development within the first quarter and can be carefully monitored within the second quarter report.
Medical gadgets had been a robust section within the first quarter with gross sales of $7.82 billion, up 4.5% year-over-year. The section might present some reduction from any weak point in different segments.
Since reporting first-quarter monetary outcomes, Johnson & Johnson has shared up to date scientific trial outcomes for a number of promising medication.
The corporate’s cell remedy Carvykti confirmed robust survival charges in a Section 3 examine. The examine might broaden the use instances for Carvykti going ahead.
In June, Johnson & Johnson shared knowledge from its Section 3 examine of Tremfya, an induction remedy to deal with Crohn’s Illness. The examine met co-primary endpoints.
With shares of Johnson & Johnson shares down 4.1% year-to-date in 2024, as seen on the chart from Benzinga Professional under, the corporate might use the earnings report and earnings name as an opportunity to focus on the drug pipeline and future development.
JNJ Worth Motion: Johnson & Johnson shares commerce at $150.51 ultimately verify Tuesday, versus a 52-week buying and selling vary of $143.13 to $175.97. Johnson & Johnson inventory is down 5.5% over the past 12 months, trailing the broader market.
Learn Subsequent:
Picture: Michael Vi by way of Shutterstock
[ad_2]
Source link
